Zemp_Mahoney 2026
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tu
mors
Chen_Doroshow 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical
Trial Update on three additional years of observation. Long-term results support
using atezolizumab to treat ASPS, even for several years; a drug holiday with careful moni-
toring may be an option for some patients.
Chen_Doroshow 2023 Updated
Atezolizumab for Advanced Alveolar Soft
Part Sarcoma: Atezolizumab was effective at inducing sustained responses in approximately one
third of patients with advanced ASPS.
Crane_Federman 2026
Alveolar Soft Part Sarcoma in Pediatric and Young Adult
Patients: A Report From the Children’s Oncology Group Study
ARST0332
Tan_Chi 2026
Camrelizumab Plus Apatinib in Advanced
Unresectable Alveolar Soft Part Sarcoma and
Undifferentiated Pleomorphic Sarcoma Patients: A
Single-Center, Exploratory Case Series
Noura_Martin-Broto 2026
Validation of a Seven-Gene Predictive SIGNature for the
Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with
Sarcoma
Eghhbali_Shirani 2025
Complete Response to Nivolumab and Ipilimumab After
Pazopanib Discontinuation in a Seven-Â Year-Â Old Girl
With Alveolar Soft Part Sarcoma: A Case Report and
Literature Review
Sicinska_Hemming 2024
ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing
Targetable Transcriptional Programs
Chen_Rosenberger 2023
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Genevois_Orbach 2024
Alveolar soft part sarcomas in young patients: The French national
NETSARC+network experience